
The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.
News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW. This week in DDW, researchers have…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.…
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and…
News Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies…
The pharmaceutical (pharma) and biopharmaceutical (biopharma) industries play a crucial role in healthcare by developing drugs and therapies to treat…
Sign in to your account